Undoubtedly, these studies underline the idea that co-targeting the tumor and the stroma poses a great opportunity to improve current anti-HER2 therapies and to overcome treatment resistances (Figure 1 and Table S4). The gene discussed is ERBB2; the disease is neoplasm.